RIPK3 and colonic neoplasm: By treating human colon cancer HT-29 cells with TNF-α, about 200,000 chemical compounds were screened for their ability to inhibit necroptosis, and MLKL was identified as a critical substrate of RIPK3 during the induction of necroptosis [28].